Oncology Vol 28 No 4_Suppl_1

(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status

April 15, 2014

Among patients with the top 10 causes of cancer death, those with Medicaid or without insurance were more likely to present with advanced-stage disease. This group also experienced worse survival when controlling for demographic information, stage at diagnosis, and receipt of definitive treatment.

(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 

April 15, 2014

Cancer treatment studies are well represented in high-impact oncology as well as general medical journals. We sought to evaluate the distribution and characteristics of oncology studies by intervention (radiation, surgery, cytotoxic chemotherapy, or targeted/systemic agents) in six high-impact oncology and general medical journals.

(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern

April 15, 2014

We have been treating patients with positive pelvic nodes with extended-field intensity-modulated radiation therapy (IMRT) to address the PA region prophylactically with a concomitant boost to the involved nodes. The purpose of this study is to assess regional control rates and recurrence patterns with this technique.

(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases

April 15, 2014

Linear accelerator-based stereotactic radiosurgery (SRS) is an effective treatment for selected melanoma patients with brain metastases. Recently, BRAF inhibitors have shown efficacy in stage IV melanoma. We sought to determine the effectiveness of SRS in patients with melanoma who are also being treated with BRAF inhibitors.

(S008) Use of Mobile Devices for Creation of Survivorship Care Plans

April 15, 2014

Cancer survivors may experience myriad late effects, and the Institute of Medicine recommends that survivorship care plans be provided to all. This study explores the willingness of health care providers (HCPs) and survivors to utilize mobile devices (MDs) for this purpose.

(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 

April 15, 2014

Temporal lobe radionecrosis is a potential complication of high-dose radiation therapy for skull base tumors. The risk of radionecrosis increases with absolute doses greater than 60 Gy, but little data are available regarding potential partial volume effects when higher-dose conventionally fractionated radiotherapy is employed.

(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers

April 15, 2014

Previous data from our institution suggest that imaging evidence of extracapsular extension, identified on pretreatment CT scans, independently predicts for worse distant control and survival for oropharyngeal squamous cell cancer (OPC) patients undergoing radiation therapy. In this present study, we sought to validate these findings in non-OPC head and neck squamous cell cancers.

(S016) Head and Neck Second Primary Cancer Rates in the HPV Era: A SEER Analysis

April 15, 2014

Our objective was to analyze the incidence of second primary cancer limited to the head and neck in a population with primary squamous cell carcinoma of the head and neck and its temporal trends in the human papillomavirus (HPV) era.

(S018) Early Tumor Perfusion Changes Predict Time to Progression in Patients With Recurrent Low-Grade Gliomas Treated With Everolimus Under a Phase II Clinical Trial

April 15, 2014

Low-grade gliomas (LGGs) are slow-growing, primary brain tumors that frequently recur after primary surgical treatment. Recent work has established the activation of the PI3K/mTOR pathway in most LGGs, raising the possibility that mTOR inhibitors, such as everolimus (RAD001), may benefit patients with LGG. Early imaging markers of treatment response and disease progression are needed to assess patients undergoing investigational therapy.

(S022) Influence of Preoperative Radiation Field on Postoperative Leak Rates in Esophageal Cancer Patients After Trimodality Therapy

April 15, 2014

Neoadjuvant chemoradiation is a standard treatment of locally advanced esophageal cancer. Preventive strategies to minimize postoperative morbidity will be important to help improve the clinical outcomes of patients. We investigated the factors associated with an increased incidence of anastomotic leaks among patients treated with neoadjuvant chemoradiation.

(S024) Correlation of Survival to CBCT-Based Tumor Response During Chemoradiation in Patients With Stage III Non–Small-Cell Lung Cancer

April 15, 2014

We evaluated the correlation between patient survival and reduction in gross tumor volume (GTV) using weekly cone-beam computed tomography (CBCT) to assess whether this could be prognostic of survival. We hypothesized that a greater percent decline in primary lung tumor volume during the course of treatment would correlate to improved patient survival.

(S025) Radiation-Induced Increases in PARP1 Activity Predict for Long-Term Radiosensitization by PARP1 Inhibition in Preclinical Breast Cancer Models

April 15, 2014

The goal of this study was to optimize combination therapy with PARP1 inhibition and radiation for clinical assessment by establishing the most effective drug/radiation treatment schedule, determining the degree of PARP1-mediated radiosensitization across a range of drug doses, and identifying early biomarkers predictive of long-term treatment efficacy in preclinical BCa models.

(S026) Postmastectomy Radiation Therapy for T3N0 Breast Cancer: A SEER Analysis

April 15, 2014

There is conflicting evidence regarding the benefit of postmastectomy radiation therapy (PMRT) for pathologic stage T3N0M0 breast cancers. We performed a Surveillance, Epidemiology, and End Results (SEER) analysis to investigate the benefit of PMRT in these patients.

(S028) Sequential Short-Course Radiotherapy and FOLFOX Chemotherapy as Preoperative Therapy for Rectal Cancer Provides Increased DFS Compared With Historical Controls

April 15, 2014

To compare rates of pathologic response, downstaging, local control, and treatment-related toxicity in patients treated in a prospective phase II trial of preoperative short-course radiotherapy and sequential FOLFOX (folinic acid, fluorouracil, oxaliplatin) chemotherapy with patients treated at our institution with preoperative long-course chemoradiotherapy and adjuvant chemotherapy.

(S029) Patient-Reported Voice and Speech Outcomes and Their Clinical and Dosimetric Predictors After Chemo-IMRT of Oropharyngeal Cancer: A Prospective Longitudinal Study

April 15, 2014

Although adverse sequelae of chemoradiation (CRT) for head and neck cancer (HNC) have been extensively detailed in recent years, the effects of CRT on voice and speech quality remain poorly characterized. We investigated changes in patient-reported voice and speech quality (VSQ) after CRT in two prospective studies of organ-sparing CRT for locally advanced oropharyngeal cancer (OPC).

(S030) Utilization of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center

April 15, 2014

To characterize the utilization of postprostatectomy radiation for patients with prostate cancer (CaP) at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center over the past decade, given the introduction of robotic prostatectomy and the publication of multiple phase III trials showing a benefit for adjuvant postprostatectomy radiation.

(S031) A Phantom-Based Simulator Approach to Improving the Quality of Prostate Brachytherapy Training

April 15, 2014

Permanent prostate brachytherapy (PPB) is a well-established treatment for localized prostate cancer. The future of PPB relies upon the quality training of future residents; however, current training requirements are frequently inadequate. Our objective was to design and implement a unique training program that utilized a phantom-based simulator to teach the process of quality assurance (QA) and improve PPB education.

(S036) The Low Alpha-Beta Ratio of Bladder Cancer: A Rationale for Hypofractionation

April 15, 2014

We hypothesized that the promising outcomes with partial-bladder treatment might be due to the effects of hypofractionation. We thus aimed to analyze the clinical impact of hypofractionation on local control and to characterize the radiation response of a bladder cancer cell line with regard to clonogenic survival.

(S037) Changes in Mass Transport as an Early Marker of Response to Cytotoxic Therapy in Human Pancreatic Adenocarcinoma

April 15, 2014

One clinical observation is that a decrease in tumor enhancement on CT scans after cytotoxic therapy is generally regarded as a good response. We hypothesized that measuring this phenomenon would correlate with local control of human pancreatic adenocarcinoma (PDAC).

(S038) Patient Tolerability and Acute Toxicity of Intensity-Modulated Radiation Therapy for Treatment of Carcinomas of the Biliary Tract

April 15, 2014

Chemoradiation for biliary tract cancers (BTCs) has been associated with substantial toxicities due to the large, irregular target volumes surrounded by critical normal tissues. The purpose of this study was to evaluate patient tolerability and acute toxicity of chemoradiation with intensity-modulated radiation therapy (IMRT) for BTCs.

(S043) RadiotypeDx: Validation of a Radiation Sensitivity Signature in Human Breast Cancer

April 15, 2014

An unmet clinical need in breast cancer (BC) management is the identification of which patients will respond to radiation therapy (RT). We hypothesized that the integration of post-RT clonogenic survival data with gene expression data across a large spectrum of BC cell lines would generate a BC-specific RT sensitivity signature predictive for RT response in BC patients and allow identification of patients with tumors refractive to conventional therapy.